GlassScriptPhysician profile
Corrine E Stokes
NPI 1457810814
$1,120.72
in general payments reported to CMS, 2019-2025
24 companies · $56.41 in 2025
The $56.41 reported for 2025 was less than what a typical Advanced Practice Midwife provider received nationally (typical 2025 total: $70.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $281 · 2022: $314 · 2023: $228 · 2024: $241 · 2025: $56.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $525.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $271.24 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $155.65 | 2022-2024 | Caplyta |
| Bayer Healthcare Pharmaceuticals INC. | $67.77 | 2021-2023 | |
| Shield Therapeutics INC | $66.13 | 2024 | |
| Organon LLC | $62.84 | 2021-2024 | |
| Exeltis, USA INC. | $50.36 | 2024-2025 | Slynd |
| Astellas Pharma US INC | $50.27 | 2023-2024 | Veozah |
| Novo Nordisk INC | $47.77 | 2021-2023 | Rybelsus, Ozempic |
| Mayne Pharma Commercial LLC | $46.85 | 2023-2024 | |
| Lilly USA, LLC | $39.20 | 2021-2024 | Emgality, Reyvow |
| Astrazeneca Pharmaceuticals LP | $35.66 | 2024 | Airsupra |
| Janssen Pharmaceuticals, INC | $28.74 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $28.39 | 2022 | |
| Dexcom, INC. | $24.31 | 2025 | Dexcom G6 Transmitter |
| Paratek Pharmaceuticals, INC. | $23.05 | 2023 | Nuzyra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $16.66 | 2023 | |
| Almatica Pharma LLC | $15.78 | 2021 | |
| Pfizer INC. | $13.96 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.77 | 2022 | |
| Idorsia Pharmaceuticals US INC | $13.66 | 2023 | Quviviq |
| Phathom Pharmaceuticals, INC. | $13.14 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $12.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $11.40 | 2021 | |
| Eisai INC. | $11.19 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corrine Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.